Several phase II clinical trials are currently ongoing to investigate their effects on advanced NSCLC, mostly in a second-line setting and combined with the EGFR tyrosine kinase inhibitor [108] (Table 2). This evidence concerns the gene EGFR and non-small cell lung carcinoma.